Editor: Marina Atanaskovic-Markovic CONFLICT OF INTEREST STATEMENT Motohiro Ebisawa received lecture fees from Viatris, Alfresa Pharma, and ARS Pharmaceuticals. Motohiro Ebisawa and Kyohei Takahashi received consulting fees from Alfresa Pharma to provide advice on drug development. The other authors declare that they have no potential conflicts of interest. PEER REVIEW For transparency, the peer review documents associated with this article are available at https://doi.org/10.1111/pai.70489.